Black carbon content in airway macrophages is associated with increased severe exacerbations and worse COPD morbidity in SPIROMICS

Vickram Tejwani1,2*, Han Woo1, Chen Liu1, Anna K. Tillery3, Amanda J. Gassett4, Richard E. Kanner5, Eric A. Hoffman6, Fernando J. Martinez7, Prescott G. Woodruff8, R. Graham Barr9, Ashraf Fawzy1, Kirsten Koehler10, Jeffrey L. Curtis11,12, Christine M. Freeman11,12, Christopher B. Cooper13, Alejandro P. Comellas14, Cheryl Pirozzi15, Robert Paine15, Donald Tashkin13, Jerry A. Krishnan16, Coralynn Sack4, Nirupama Putcha1, Laura M. Paulin17, Marina Zusman4, Joel D. Kaufman4, Neil E. Alexis3 and Nadia N. Hansel1

Abstract

Background Airway macrophages (AM), crucial for the immune response in chronic obstructive pulmonary disease (COPD), are exposed to environmental particulate matter (PM), which they retain in their cytoplasm as black carbon (BC). However, whether AM BC accurately reflects environmental PM2.5 exposure, and can serve as a biomarker of COPD outcomes, is unknown.

Methods We analyzed induced sputum from participants at 7 of 12 sites SPIROMICS sites for AM BC content, which we related to exposures and to lung function and respiratory outcomes. Models were adjusted for batch (first vs. second), age, race (white vs. non-white), income (<$35,000, $35,000~$74,999, ≥$75,000, decline to answer), BMI, and use of long-acting beta-agonist/long-acting muscarinic antagonists, with sensitivity analysis performed with inclusion of urinary cotinine and lung function as covariates.

Results Of 324 participants, 143 were current smokers and 201 had spirometric-confirmed COPD. Modeled indoor fine (<2.5 μm in aerodynamic diameter) particulate matter (PM2.5) and urinary cotinine were associated with higher AM BC. Other assessed indoor and ambient pollutant exposures were not associated with higher AM BC. Higher AM BC was associated with worse lung function and odds of severe exacerbation, as well as worse functional status, respiratory symptoms and quality of life.

Conclusion Indoor PM2.5 and cigarette smoke exposure may lead to increased AM BC deposition. Black carbon content in AMs is associated with worse COPD morbidity in current and former smokers, which remained after sensitivity analysis adjusting for cigarette smoke burden. Airway macrophage BC, which may alter macrophage function, could serve as a predictor of experiencing worse respiratory symptoms and impaired lung function.

*Correspondence:
Vickram Tejwani
tejwanv@ccf.org

Full list of author information is available at the end of the article.
Background
Chronic obstructive pulmonary disease (COPD) is characterized by recurrent exacerbations and progressive decline in lung function due in part to abnormal inflammatory responses of the airways to noxious particles or gases [1–3]. In developed countries, the most strongly supported cause of COPD is cigarette smoking; however, there is growing evidence that other environmental exposures, particularly ambient and indoor air pollution, are linked to cardiopulmonary morbidity and mortality [4, 5]. Inhaled fine (<2.5 μm in aerodynamic diameter) particulate matter (PM_{2.5}) reaches the surfaces of the central airways where airway macrophages (AM) reside. AM, which play a critical role in immune response and tissue repair in COPD, are exposed to particles which are phagocytosed and retained in the cytoplasmic material [6–8]. Both cigarette smoke [9] and the carbonaceous core that commonly comprises particulate matter PM_{2.5} can be visualized within AM [10]. Thus, AM black carbon (BC)–quantified as mean BC cross-sectional area (μm²) per macrophage—may serve as a biomarker for airborne PM pollutant and tobacco smoke exposure. This has the potential to estimate prior exposures without requiring the burdensome and complex process of direct in-home measurements.

Hence, cytopathologic techniques that examine macrophages collected from induced sputum may have the ability to assess an individual’s inhaled dose of particles [11, 12]. In single center studies, inhaled smoke from combusted biomass and indoor PM have been linked to higher AM BC in healthy volunteers and former smokers with COPD, respectively [13, 14]. We also recently reported an association of AM BC area with increased severe exacerbations and nominally worse lung function among a small cohort of former smokers with COPD [15].

However, AM BC has previously been examined primarily in small studies in a single geographic location, limiting definitive conclusions regarding exposure contributions to AM BC content and its association with respiratory outcomes. Additionally, macrophages vary in size [16, 17] and therefore, the percent of macrophage occupied by black carbon rather than absolute area may be relevant – however, most studies did not assess AM BC percent area. We sought to assess the relationship between ambient and indoor pollutant exposures and AM BC (quantified as area and percent area) in former and current smokers from the Subpopulations and Intermediate Outcome Measures In COPD Study Air Pollution (SPIROMICS AIR) Study and to assess further the relationship of AM BC and COPD morbidity. We hypothesized that smoking and particulate exposure lead to AM BC which may lead to worse COPD morbidity given dysregulated macrophage function.

Methods
SPIROMICS-AIR cohort
SPIROMICS (ClinicalTrials.gov NCT01969344) is a prospective observational cohort study with the goals of identifying new COPD subgroups and intermediate markers of disease progression. SPIROMICS AIR added air pollution exposure assessment to estimate individual-level outdoor and indoor air pollution exposures in a subgroup of participants. Subjects for SPIROMICS AIR were enrolled from 2010 to 2016, phenotyped and followed at seven centers [18]. SPIROMICS participants were 40–80 years of age at baseline, who were either healthy persons with a smoking history of ≤1 pack-year (“never smokers”) and no known current lung disease or current or former smokers (≥20 pack-years) with and without evidence of obstructive lung disease. Given our focus on those with or at risk of COPD, never smokers were not included in this analysis. Informed written consent was obtained from all participants, all experiments were performed in accordance with relevant guidelines and regulations, and the study was approved by the IRB and ethics committee of each site (e-Table 1).

We categorized participants as having either no spirometric evidence of airflow obstruction or having COPD (postbronchodilator FEV₁/FVC <70%) with Global Initiative for Chronic Obstructive Lung Disease (GOLD) stage I/II (FEV₁ ≥50% predicted) or GOLD stage III/IV (FEV₁ <50% predicted) disease. A concomitant asthma diagnosis was not an exclusion criterion, however participants were queried regarding a history or diagnosis of asthma. Those with other non-COPD obstructive lung disease were excluded.

Airway macrophage black carbon assessment
Sputum induction was performed according to the methods of Alexis et al. [19]. Three hundred sixty-three subjects at SPIROMICS AIR sites with a post bronchodilator FEV₁ >35%, underwent sputum induction. Of these, 17 never smokers were excluded and 22 had slides that were poor quality or did not have an adequate number of macrophages leaving 324 subjects selected for BC analysis. Cytospin samples were prepared as outlined in the Online Supplement. A total of 50 AM, identified by morphology and with an intact cell wall irrespective of BC content, were randomly selected per participant. The 50 AM were analyzed for BC by a trained technician blinded to environmental exposure assessment and clinical

Keywords Macrophage, Black carbon, COPD
outcomes. Processing slides in two batches, we quantified AM BC both as mean cross-sectional area (um²) per macrophage and as mean percent area BC per macrophage which is the cross-sectional area of BC divided by the cross-sectional area of the macrophage [14, 20].

**Exposure assessment**

Estimation of ambient outdoor concentrations of PM$_{2.5}$, nitrogen dioxide (NO$_2$) and ozone outside of each participant’s residential addresses, which relied on spatio-temporal modelling as described in the Online Supplement, were available for 284 participants [21, 22]. For this analysis, ambient exposures were averaged over the one month prior to sputum induction and BC quantification.

Modeled indoor air pollutant concentration (PM$_{2.5}$, NO$_2$ and nicotine) estimates were available for 170 participants, using models generated from SPIROMICS as previously described [23] and as described in the Online Supplement. When compared to the measured concentrations available on a subset of patients, the models explained 60%, 63% and 61% of variability in PM$_{2.5}$, NO$_2$ and indoor nicotine, respectively [23]. Urinary cotinine was also measured at the study visit using quantitative liquid chromatography-tandem mass spectrometry (ARUP Laboratories, Salt Lake City, UT). Current and former smokers were defined based on a urinary cotinine cutoff of 31 ng/mL which has been shown to have a sensitivity of 97.1% and specificity of 93.9% for active smoking [24]. We also specifically queried participants regarding exposures to vapors, gases, dusts, or fumes (VGDF).

**Spirometric and clinical assessment**

Spirometry before and after bronchodilator was performed according to standard guidelines [25] and reviewed for quality control and assurance. Exacerbations were assessed prospectively for one-year by quarterly phone calls. We defined exacerbation as worsening respiratory symptoms requiring antibiotics or oral steroids, and severe exacerbations as leading to an emergency department visit or hospitalization.

On the same day as sputum collection, health information was collected through validated questionnaires; specifically, the St. George’s Respiratory Questionnaire (SGRQ), [26] COPD Assessment Test (CAT), [27] the modified Medical Research Council (mMRC) Dyspnea Scale [28] and ease of cough and sputum questionnaire [29]. We defined chronic bronchitis by a positive response to either the classic or alternative SGRQ definition [30]. Functional exercise capacity was assessed by the 6 min walk distance (6MWD), performed according to American Thoracic Society criteria [31].

**Statistical analysis**

We used descriptive statistics to characterize sample participants with AM BC data and compare their characteristics to the larger SPIROMICS cohort.

To assess the relationship between AM BC and indoor PM$_{2.5}$, we ran a linear regression of BC area or BC percent on indoor PM$_{2.5}$ using generalized linear mixed model with random effect for study sites. The models were minimally adjusted for batch (first vs. second) and fully adjusted for batch, age, race, income, BMI, and long-acting beta-agonist or long-acting muscarinic antagonist (LABA/LAMA) use (see Online Supplement for additional detail). Pack-years was considered as a covariate but given it was not associated with either AM BC percent or area, we did not include it in our model. Sensitivity analysis was conducted using urinary cotinine as a covariate in the fully adjusted models. As secondary analysis, other environmental exposures (indoor NO$_2$, indoor nicotine, urinary cotinine, VGDF exposure (yes/no), ambient PM$_{2.5}$, ambient NO$_2$, and ambient ozone) were assessed for their associations with BC area or BC percent one at a time using the same regression approach.

To assess the relationship between COPD outcomes and AM BC, linear regression for continuous COPD outcomes and logistic regression of any or severe exacerbations and chronic bronchitis was run on BC area or BC percent using a generalized linear mixed model with random effect for study sites. All models were adjusted for batch, age, sex, race, income, BMI, and LABA/LAMA use (see Online Supplement). For severe exacerbation model only, due to low number of reported events, the covariates were limited to batch without random site effect. In sensitivity analysis, urinary cotinine and FEV1% predicted were additionally adjusted as a covariate one at a time. To assess whether the association between COPD outcomes and AM BC varied by smoking status, a two-way interaction model was run by adding the interaction between dichotomous smoking status ($>$ or $\leq$31.5 ng/mL urinary cotinine level [24]) and BC area or BC percent to the fully adjusted model. Given cotinine can be influenced by nicotine replacement therapy, analyses were also repeated by self-reported smoking status. Additionally, stratified analyses by smoking status were performed (see Online Supplement). For all regression analyses, linearity and normality assumptions were checked where appropriate and transformations made as needed (see Online Supplement).

All analyses were completed using STATA version 15.1 (College Station, TX). Statistical significance was defined as P<0.05 for main and interaction effect.
Results

Participant characteristics

Participants had a mean (SD) age of 63.6 (8.8) years (Table 1). 41% of the participants were female, 81% were white, and 69% had education beyond high school. About half of the participants (44%) self-reported as current smokers, but 160 (50%) had urinary cotinine >31.5 ng/mL. In the year prior to baseline visit, 16.1% and 6.9% of the participants had a urinary cotinine <31.5 ng/mL, whereas 89% of self-reported former smokers had a urine cotinine <31.5 ng/mL. In the year prior to baseline visit, 16.1% and 6.9% of the participants reported any and severe exacerbations, respectively.

The mean (SD) BC area was 80.68 (70.56) µm² [median (Q1-Q3)=61.7 (44.8–87.8)] and BC percent 13.29 (6.45)%. The participants in our analysis had less severe disease but a similar pack-year history and exposure burden, compared to all participants in the SPIROMICS cohort with an FEV₁ >35% predicted (e-Table 2).

Environmental exposure association with macrophage black carbon

Two hundred eighty-five (88%) participants had modeled indoor and ambient pollutant estimates. The mean (SD) modeled indoor PM₂.₅ and NO₂ concentration were 12.00 (10.16) µg/m³ and 11.44 (4.86) ppb, respectively. Modeled indoor airborne nicotine had a mean (SD) of 33.96 (22.28) µg/m³, and 142 (44.2%) reported vapor dust gas fume (VDGF) exposure. The modeled mean (SD) ambient PM₂.₅, NO₂, and ozone concentration over the month prior to quantification were 8.75 (2.95) µg/m³, 11.11 (7.35) ppb, and 26.14 (8.23) ppb respectively. There was generally no difference in participant characteristics between those with and without estimates of air pollutant exposure except for education and income level (e-Table 3).

In the minimally adjusted model, adjusted for processing batch, a one SD greater (10.16 µg/m³) estimated indoor PM₂.₅ concentration was associated with higher BC area (β = 9.96%, 95% CI: 0.47%, 20.4%) and higher BC percent (β = 13.1%, 95% CI: 3.49%, 23.6%). When fully adjusted, indoor PM₂.₅ concentration was nominally associated with higher BC area (β = 7.78%, 95% CI: -0.96%, 17.3%, P=0.082) (Fig. 2) and was significantly associated with a higher BC percent (β = 10.7%, 95% CI: 1.64%, 20.6%).

Urinary cotinine also was nominally associated with a higher BC area (β = 9.70%, 95% CI: -0.97%, 21.5%, P=0.076) for a one SD rise and was statistically significantly associated with a higher BC percent (β = 10.7%, 95% CI: 2.24%, 19.9%) for a one SD rise in the fully adjusted model. There was no association of indoor NO₂, indoor nicotine, VDGF, ambient PM₂.₅, ambient NO₂ or ambient ozone with BC area or BC percent in either minimally adjusted or fully adjusted models (Table 2).

Association of black carbon area with COPD outcomes

All 324 participants were included in the health outcomes analysis. After adjustment for covariates, a one SD higher (70.6 µm²) AM BC area was associated with lower FEV₁ % predicted (β = -2.17, 95% CI: -3.82, -0.52) and greater odds of a severe exacerbation over one year (OR = 1.52, 95% CI: 1.01, 2.28) (Fig. 3). Higher BC area was not associated with odds of any exacerbation. Higher AM BC area was associated with worse respiratory morbidity including worse CAT (β = 1.04, 95% CI: 0.39, 1.68), mMRC (β = 0.11, 95% CI: 0.02–0.19), SGRQ (β = 2.59, 95% CI: 1.13–4.05), increased cough and sputum (β = 0.43, 95% CI: 0.21–0.65).

Table 1: Participant Characteristics, N = 324

| Characteristic                        | Mean ± SD or n (%) |
|--------------------------------------|--------------------|
| Age, yrs                             | 63.58 ± 8.78       |
| Sex, n (% female)                    | 134 (41.4%)        |
| Race, n (% white)                    | 260 (80.7%)        |
| Education, n (% > HS grad)           | 223 (69.0%)        |
| Annual Household Income              |                    |
| <$35,000                             | 116 (35.8%)        |
| $35,000 - $74,999                    | 101 (31.2%)        |
| $75,000                              | 62 (19.1%)         |
| Decline to answer                    | 45 (13.9%)         |
| Body Mass Index, kg/m²               | 28.50 ± 5.07       |
| Medication LABA/LAMA, n (%)          | 87 (27.1%)         |
| Smoking (pack-years)                 | 47.76 ± 22.46      |
| FEV₁, percent predicted              | 84.30 ± 18.96      |
| Current Smoker, n (%)                | 143 (44.4%)        |
| Urinary Cotinine, ng/mL              | 597.70 ± 851.23    |
| VGDF, n (%)                          | 142 (44.2%)        |
| ICS, n (%)                           | 69 (21.5%)         |
| OCS, n (%)                           | 2 (0.6%)           |
| CAT score                            | 12.31 ± 7.72       |
| mMRC score                           | 0.83 ± 0.82        |
| SGRQ score                           | 28.26 ± 19.34      |
| ECSC                                 | 9.16 ± 3.49        |
| 6MW, meters                          | 432.99 ± 101.29    |
| Any exacerbations in the prior 12mo, n (%) | 51 (16.1%)     |
| Severe exacerbations in the prior 12mo, n (%) | 22 (6.9%)       |
| Any exacerbations over 12mo follow-up, n (%) | 36 (11.9%)     |
| Severe exacerbations over 12mo follow-up, n (%) | 8 (2.6%)          |
| Sputum Cell Differential             |                    |
| Neutrophil %                         | 59.81 ± 21.77      |
| Macrophage %                         | 37.37 ± 20.65      |
| Eosinophils %                        | 0.98 ± 2.27        |
| Lymphocytes %                        | 0.11 ± 0.24        |
| Basophils %                          | 0.00 ± 0.03        |
| Bronchial epithelial cells %         | 1.94 ± 3.69        |
| Asthma                               |                    |
| Never had asthma, n (%)             | 243 (75.0%)        |
| Diagnosed with asthma, n (%)         | 61 (18.9%)         |
| Don’t know if had asthma, n (%)      | 20 (6.2%)          |
CI: 0.10–0.70), shorter 6MWD ($\beta$= -14.2, 95% CI: -17.2, -11.2) and greater odds of chronic bronchitis (OR=1.50, 95% CI: 1.04–2.18) (Table 3). In sensitivity analysis, adjusting for urinary cotinine, the results remained generally robust (e-Table 4). The association between severe exacerbation and AM BC area remained similar in magnitude and direction but was no longer statistically significant (OR=1.47, 95% CI: 0.97, 2.22, P=0.068). In each sensitivity analysis, there was some suggestion of attenuation in the relationships across the outcomes, but the adjustment did not alter the conclusions.

**Association of black carbon percent with COPD outcomes**

A one SD higher (6.5 percentage point) AM BC percent with severe exacerbations was no longer statistically significant but remained similar in magnitude and direction (OR=1.48; 95% CI: 0.95, 2.29, P=0.08). In each sensitivity analysis, there was some suggestion of attenuation in the relationships across the outcomes, but the adjustment did not alter the conclusions.

**Fig. 2 An increase in indoor PM2.5 concentration is associated with an increase in AM black carbon levels.** The chart shows the predicted levels of (A) black carbon area and (B) black carbon percent and their 95% confidence intervals, based on multivariable regression analysis of log-transformed AM black carbon on indoor PM2.5, adjusted by batch, age, race, income, BMI, and LABA/LAMA. The predicted values were exponentiated to show the AM black carbon in original unit-scaling in y-axis.

**Fig. 1 Histograms showing distribution of black carbon area and black carbon percent**
Table 2: Association of environmental exposures with black carbon area and black carbon percent

| Exposure          | Predicted Change (95% CI) in Black Carbon Area | Predicted Change (95% CI) in Black Carbon Percent |
|-------------------|-----------------------------------------------|-----------------------------------------------|
|                   | Minimally Adjusted† | Fully Adjusted† | Minimally Adjusted† | Fully Adjusted† |
| Indoor PM<sub>2.5</sub> | 10.0% (0.5%, 20.4%) | 13.1% (3.5%, 23.6%) | 10.7% (1.6%, 20.6%) |
| Indoor NO<sub>2</sub>   | 3.5% (-4.5%, 9.5%) | 3.4% (-4.5%, 9.5%) | 1.5% (1.5%, 7.9%) |
| Indoor Nicotine      | 4.4% (-2.6%, 2.7%) | 5.0% (-2.8%, 8.6%) | 2.9% (2.9%, 11.6%) |
| Urinary Cotinine     | 11.1% (3.1%, 19.7%) | 12.5% (5.3%, 20.2%) | 10.7% (2.2%, 19.9%) |
| VGDF (yes/no)        | -0.2% (-1.0%, 1.1%) | 2.9% (-1.2%, 6.0%) | 1.0% (0.0%, 2.0%) |
| Ambient PM<sub>2.5</sub> | 1.4% (-4.2%, 8.6%) | -0.7% (-3.0%, 2.7%) | -0.9% (-4.4%, 2.7%) |
| Ambient NO<sub>2</sub> | 1.5% (-3.1%, 6.3%) | -0.3% (-4.4%, 3.4%) | -1.6% (-6.4%, 3.4%) |
| Ambient Ozone        | -0.08% (-0.7%, 7.3%) | 0.9% (-3.0%, 4.9%) | 1.7% (-3.3%, 7.0%) |

The effect estimates represent the predicted change in log AM BC, expressed in percentage change in original unit scaling, per 1 SD rise in the level (µg/m³) of the environmental exposure.

†Adjusted for batch (first vs. second), age, race (white vs. non-white), income (<$35,000, $35,000–$74,999, ≥$75,000), decline to answer, BMI, and LABA/LAMA use (yes vs. no)

Interaction with smoking

There was interaction between BC area and smoking status (by urinary cotinine ≤vs. >31.5 ng/mL) for cough and sputum (P<0.001) and odds of chronic bronchitis (P<0.033), such that the adverse association between AM BC area and the outcomes were stronger among current smokers than among former smokers. There was no other significant interaction for the remaining outcomes and no significant interaction between AM BC percent and smoking status for any measured outcomes (e-Table 6). Findings were similar (e-Table 7) when smoking status was characterized by self-report smoking status rather than urinary cotinine.

Discussion

This study of former and current smokers in a multicenter cohort identified a positive association of indoor modeled PM<sub>2.5</sub> and urinary cotinine with AM BC in induced sputum specimens. Additionally, AM BC area was associated with worse FEV<sub>1</sub>% predicted after adjusting for both previous and current cigarette smoking, as well as greater odds of a severe exacerbation. Airway macrophage BC was also associated with a shorter 6MWD, worse patient-reported outcomes and a higher likelihood of chronic bronchitis. This expands our current understanding of AM BC to serve as both a biomarker of environmental exposures as well as worse respiratory morbidity.

Compared to other studies of AM BC obtained via induced sputum, [14, 15, 32] participants from this study had a higher observed BC deposition. This may be because those studies were of children or former smokers with COPD. We have previously shown that indoor PM concentrations directly measured at participants’ residence are associated with AM BC area, [14] however in our current study utilizing indoor exposure estimates modelled on questionnaire and ambient meteorological data, we identified an association with AM BC percent and a directionally, although not statistically significant association with AM BC area in fully adjusted models. The absence of direct measurements of indoor exposures likely explains the weaker association between modeled indoor PM<sub>2.5</sub> and BC area. Notably, urinary cotinine was also associated with AM BC suggesting cigarette smoke inhalation as a prominent contributing exposure. Further, the association between modeled indoor PM<sub>2.5</sub> and BC was attenuated with inclusion of urinary cotinine as a covariate suggesting part, but not all, of the indoor PM which contributes to AM BC may be driven by smoking. Future studies may include never smokers to further adjudicate this possibility. Given that previous studies with measured indoor PM<sub>2.5</sub> showed associations with AM BC even in non-smoking homes, [14] and the lack of association between indoor nicotine and BC in our current study, it is unlikely the association between

(β= -2.43, 95% CI: -5.21, 0.35) and greater odds of a severe exacerbation over one year (OR=2.19, 95% CI: 1.04, 4.63). Higher BC percent was not associated with odds of any exacerbation. Higher AM BC percent was associated with worse mMRC (β=0.11, 95% CI: 0.03,0.18), worse cough and sputum (β=0.51, 95% CI: 0.05–0.96), shorter 6MWD (β=−13.2, 95% CI: -21.4, -4.92), and greater odds of chronic bronchitis (OR=1.53, 95% CI: 1.13, 2.08). Higher AM BC percent was nominally associated with worse CAT and SGRQ, but these associations were not statistically significant (Table 3). Adjustment by urinary cotinine and by FEV1% predicted, in separate sensitivity analysis, did not alter the conclusion, though there was some evidence that the associations were attenuated (e-Table 4, e-Table 5).
indoor PM and BC is driven solely by cigarette smoke exposure. In terms of the role of ambient PM exposures, studies have shown that in children with asthma, ambient PM<10 μm in aerodynamic diameter was weakly associated with AM BC [32]. This may be given BC is a reflection of combustion exposure which is predominantly in the fine particulate size. This study’s findings are consistent with prior studies of adults that demonstrated indoor – but not ambient – exposures to biomass fuel [13] or PM_{2.5} [14] are associated with increased AM BC. This may be due to the large amount of time that most adults spend indoors [33]. Lastly, we did not account for marijuana exposure which may also contribute to AM BC [34].

The impact of AM BC area on respiratory disease morbidity in COPD has been largely unexplored beyond a small single center study of former smokers with COPD demonstrating an association with increased risk of severe exacerbations and nominally worse lung function which did not identify an association with other COPD outcomes [15]. This study also identified a similar association with greater odds of a severe exacerbation. Furthermore, consistent with that prior study of former smokers with COPD [15] and a study by Kulkarni et al. of children with asthma [32] we identified an association with worse lung function. There is no established MCID for FEV₁ % predicted, however regulators have noted a change of 5–10% of change from baseline is considered to be clinically important [35]. The BC area in our participants ranged from 20.3 to 759.8 (Fig. 1) which corresponds to an estimated 22.7% change in FEV₁ % predicted per our model in going from the lowest to the highest BC area.

Percentages of alveolar [36] and airway [37] macrophages are increased in individuals with COPD, however by randomly selecting 50 macrophages, AM content should not be influenced by the total number or percent
Table 3 Association of black carbon area and black carbon percent with primary and secondary outcomes

| Outcome                          | Black Carbon Area Effect Estimate (95% CI) Per 1 SD Rise | Black Carbon Percent Effect Estimate (95% CI) Per 1 SD Rise |
|---------------------------------|----------------------------------------------------------|-----------------------------------------------------------|
| **Primary Outcomes**            |                                                          |                                                          |
| FEV<sub>1</sub>, percent predicted | -2.17 (-3.82, -0.52)                                     | -2.43 (-5.21, 0.35)                                      |
| Any Exacerbation over one year, OR | 1.02 (0.81, 1.29)                                        | 1.05 (0.77, 1.42)                                       |
| Severe Exacerbation over one year, OR | 1.52 (1.01, 2.28)                                       | 2.19 (1.16, 4.14)                                       |
| **Secondary Outcomes**          |                                                          |                                                          |
| CAT score                       | 1.04 (0.39, 1.68)                                         | 1.04 (-0.03, 2.11)                                      |
| mMRC score                      | 0.11 (0.02, 0.19)                                         | 0.11 (0.03, 0.18)                                       |
| SGRQ score                      | 2.59 (1.13, 4.05)                                         | 2.95 (-0.09, 5.98)                                      |
| ECSC score                      | 0.43 (0.10, 0.75)                                         | 0.51 (0.05, 0.96)                                       |
| 6MWD, m                         | -14.17 (-17.18, -11.15)                                  | -13.15 (-21.39, -4.92)                                 |
| **Chronic Bronchitis, OR**      | 1.50 (1.04, 2.18)                                         | 1.53 (1.13, 2.08)                                      |

The effect estimates represent the predicted change in each continuous COPD outcome or the odds ratio of exacerbations or chronic bronchitis per 1 SD rise in the level of AM BC measure. The models were adjusted for batch (first vs. second), age, race (white vs. non-white), income (<$35,000, $35,000–$74,999, ≥$75,000), decline to answer, BMI, and LABA/LAMA use (yes vs. no), with random effect for study sites. For the severe exacerbation model only—due to low number of events, the covariates were limited to batch, without random site effect.

Table 3 shows the association of black carbon area and black carbon percent with primary and secondary outcomes. The effect estimates represent the predicted change in each continuous COPD outcome or the odds ratio of exacerbations or chronic bronchitis per 1 SD rise in the level of AM BC measure. The models were adjusted for batch, age, race, income, BMI, and LABA/LAMA use (yes vs. no), with random effect for study sites. For the severe exacerbation model only—due to low number of events, the covariates were limited to batch, without random site effect.

of macrophages. Given the increase in overall macrophage count, there will be an increase in total carbon and therefore AM carbon effect may be amplified in individuals with COPD. Prior studies have typically utilized the mean carbon area per macrophage, [13–15, 20] which does not account for variation in macrophage area. However, a recent study assessing both BC area and BC percent identified stronger associations between seven day PM<sub>2.5</sub> exposures and BC percent (compared to BC area) [38]. Our study also yielded stronger associations for environmental exposures and BC percent. We speculate that given BC percent intrinsically accounts for variation in macrophage size, it may be a more appropriate measure of exposures and overall BC deposition. The magnitudes of associations for both BC area and percent with clinical outcomes were similar, however the confidence intervals were wider for BC percent. These wider confidence intervals may be due to lower coefficient of variation (less dispersion around the mean) for BC percent as an independent variable—which inversely impacts the power of regression analysis—and might underpin why some associations between BC percent and clinical outcomes were not statistically significant. However, at this juncture both may be relevant biomarkers and it is premature to determine superiority of one measure compared to another.

Our study included both current and former smokers and notably, there was no effect modification by smoking status on any clinical outcomes except for the association of BC with chronic bronchitis and cough and sputum, with the deleterious effects more pronounced in current smokers. Black carbon associations with worse COPD outcomes were identified after adjusting for urinary cotinine and we therefore postulate that independent of smoking, BC serves as a useful biomarker reflecting worse disease outcomes, potentially due to direct deleterious effects on macrophage function, [15] promoting a more pro-inflammatory airway profile, [38] or increasing Th17 immunity [9].

The strength of our study lies in the comprehensive phenotype data, geographically diverse population and large sample size with former and current smokers that allowed for exploration of effect modification by smoking status. There are limitations of this study that merit discussion. Although we used a validated model of indoor exposures, we did not have direct measurements. The FEV<sub>1</sub>% predicted of >35% in our cohort may not generalize to patients with more severe COPD. Additionally, we measured AM BC at a single time-point. Although the exact lifespan of human AM is unknown, 6-month exposures are most strongly associated with AM BC area [39] and in a case report following bone marrow transplantation, patients’ AMs disappeared linearly, with their lifespan being approximately 81 days [40]. Therefore, the 2 weeks to 1 month exposures estimates should be reflected in our BC quantification, as should the cross-sectional effect of BC on clinical outcomes. Furthermore, sputum macrophages represent a heterogenous mixture of cell age and maturation state, thus reducing any potential lifespan bias. Assessing odds of exacerbations over twelve months is longer than the reported AM lifespan however, no prior longitudinal study has identified significant within person variation of AM BC [14]. Additionally, there was a limited number of severe exacerbations which hindered our ability to adjust for confounders in our severe exacerbation model.

This study demonstrates modeled indoor PM<sub>2.5</sub> and urinary cotinine are associated with increased AM BC, and increased AM BC is associated with worse lung function and greater odds of severe exacerbation, as well as worse COPD outcomes, shorter 6MWD and higher likelihood of chronic bronchitis. Therefore, beyond solely serving as a marker for increased environmental exposures, AM BC, independent of smoking status, is associated with higher disease burden, suggesting a direct deleterious effect of BC on AM in COPD. This study furthers our understanding of the influence of AM BC content on COPD morbidity.

Abbreviations

| Abbreviation | Description |
|--------------|-------------|
| 6MWD         | 6 min walk distance |
| AM           | Airway macrophages |
| BC           | Black carbon |
under license for the current study, and so are not publicly available. Data but restrictions apply to the availability of these data, which were used The data that support the findings of this study are available from SPIROMICS Biopharma and Mylan. Inc.; Sanofi; Sunovion; Takeda Pharmaceutical Company; and Theravance Corporation; Nycomed GmbH; ProterixBio; Regeneron Pharmaceuticals, the Foundation for the NIH and the COPD Foundation from AstraZeneca/and U24 HL141762, and supplemented by contributions made through HHSN268200900017C, HHSN268200900018C, HHSN268200900019C, HHSN268200900014C, HHSN268200900015C, HHSN268200900016C, HHSN268200900011C, HHSN268200900010C, from the NIH/NHLBI grant numbers U01 HL137880 and U24 HL141762, and supplemented by contributions made through the Foundation for the NIH and the COPD Foundation from AstraZeneca/ MedImmune; Bayer; Bellerophon Therapeutics; Boehringer-Ingelheim Pharmaceuticals, Inc.; Chiesi Farmaceutici S.p.A.; Forest Research Institute, Inc.; GxOxSmithKline; Genfils Therapeutics, Inc.; Ikaria, Inc.; Novartis Pharmaceuticals Corporation; NymcodeM GmbH; ProteinBio; Regenerate Pharmaceuticals, Inc.; Sanofi, Sunovion; Takeda Pharmaceutical Company; and Theravance Biopharma and Mylan.

Data sharing
The data that support the findings of this study are available from SPIROMICS but restrictions apply to the availability of these data, which were used under license for the current study, and so are not publicly available. Data are however available from the authors upon reasonable request and with permission of SPIROMICS investigators.

Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s12931-022-02225-0.

Acknowledgements
The authors thank the SPIROMICS participants and participating physicians, investigators, and staff for making this research possible. More information about the study and how to access SPIROMICS data is at www.spiromics.org. Current and former investigators of the SPIROMICS sites and reading centers: Neil E. Alexis, Wayne H. Anderson, Mehrdad Arjomand, Igor Barjakarevic, R. Graham Bart, Lori A. Bateman, Surya P. Bhatt, Eugene R. Bleecker, Richard C. Boucher, Russell P. Bowler, Stephanie (A) Christensen, Alejandro P. Cornellas, Christopher (B) Cooper, David J. Couper, Gerard J. Criner, Ronald G. Crystal, Jeffrey L. Curtis, Claire M. Doerschuk, Mark T. Dransfield, Brad Drummond, Christine M. Freeman, Craig Galban, MeiLan K. Han, Nadia N. Hansel, Annette T. Hastie, Eric A. Hoffman, Yvonne Huang, Robert J. Kaner, Richard E. Kanner, Eric C. Kleerup, Jerry A. Krishnan, Lisa M. LaVange, Stephen C. Lazarus, Fernando J. Martinez, Deborah A. Meyers, Wendy C. Moore, John D. Newell Jr., Robert Paine III, Laura Paulin, Stephen P. Peters, Cheryl Pirozzi, Nirupama Putcha, Elizabeth C. Oelsner, Wanda K. O’Neal, Victor E. Ortega, Sanjeev Raman, Stephen I. Rennard, Donald P. Tashkin, J Michael Wells, Robert A. Wise,and Prescott G. Woodruff. Project officers from the Lung Division of the National Heart, Lung, and Blood Institute: LisaPostow and Lisa Viviano.

Contributorship statement
VT, HW, NEA and NNH contributed to the conception and design of the study, interpretation of results, drafting and revising the manuscript. AKT, AIG, REK, EH, FJM, PGW, RGB, J.C., CMW, CBC, APC, CP, RP, DT, JAK, MZ, JK and NNH contributed to the acquisition of the data. CL, AF, KK, CS, NF, KP, MZ, and JK contributed to interpretation of the results and revisions of the manuscript for critically important intellectual content. All of the authors approved this version of the manuscript to be published and agree to be accountable for all aspects of the work.

Funding support
This work was supported by grants from the National Heart, Lung, and Blood Institute grant number F32HL149258-01 (VT). The Subpopulations and Intermediate Outcome Measures in COPD Study (SPIROMICS) was supported by contracts from the NIH/NHLBI (HHSN268200900013C, HHSN268200900014C, HHSN268200900015C, HHSN268200900016C, HHSN268200900017C, HHSN268200900018C, HHSN268200900019C, HHSN268200900020C), from the NIH/NHLBI grant numbers U01 HL137880 and U24 HL141762, and supplemented by contributions made through the Foundation for the NIH and the COPD Foundation from AstraZeneca/ MedImmune; Bayer; Bellerophon Therapeutics; Boehringer-Ingelheim Pharmaceuticals, Inc.; Chiesi Farmaceutici S.p.A.; Forest Research Institute, Inc.; GxOxSmithKline; Genfils Therapeutics, Inc.; Ikaria, Inc.; Novartis Pharmaceuticals Corporation; NymcodeM GmbH; ProteinBio; Regenerate Pharmaceuticals, Inc.; Sanofi, Sunovion; Takeda Pharmaceutical Company; and Theravance Biopharma and Mylan.

Data sharing
The data that support the findings of this study are available from SPIROMICS but restrictions apply to the availability of these data, which were used under license for the current study, and so are not publicly available. Data

are however available from the authors upon reasonable request and with permission of SPIROMICS investigators.

Declaration

Ethics approval and consent to participate
All participants signed an informed consent. All studies were approved by ethics and review boards (Institutional Review Boards) at all participating centers.

Competing interests
There are no competing interests for any author.

Consent for publication
Not applicable.

Author details
1Division of Pulmonary and Critical Care Medicine, Johns Hopkins University, Baltimore, MD, USA
2Respiratory Institute, Cleveland Clinic, 9500 Euclid Avenue, A90, 44195 Cleveland, OH, USA
3Center for Environmental Medicine, Asthma, and Lung Biology, Division of Allergy and Immunology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
4Division of Pulmonary and Critical Care Medicine, University of Washington, Seattle, WA, USA
5Division of Respiratory, Critical Care and Occupational Medicine, University of Utah, Salt Lake City, UT, USA
6Department of Radiology, Medicine and Biomedical Engineering, University of Iowa, Iowa City, IA, USA
7Division of Pulmonology and Critical Care Medicine, Weill-Cornell Medical Center, Cornell University, New York, NY, USA
8Department of Medicine, Columbia University College of Physicians and Surgeons, New York, New York, New York, USA
9Environmental Health and Engineering, Johns Hopkins University, Baltimore, MD, USA
10Pulmonary and Critical Care Medicine Division, Department of Internal Medicine, University of Michigan Health System, Ann Arbor, MI, USA
11Veterans Affairs Ann Arbor Healthcare System, Ann Arbor, MI, USA
12Division of Pulmonary and Critical Care Medicine, University of California Los Angeles Medical Centers, Los Angeles, CA, USA
13Division of Pulmonary, Critical Care, and Occupational Medicine, College of Medicine, University of Iowa, Iowa City, IA, USA
14University of Utah Hospital, Salt Lake City, UT, USA
15Department of Medicine, University of Illinois at Chicago, Chicago, IL, USA
16Pulmonary/Critical Care, Dartmouth Hitchcock Medical Center, Lebanon, NH, USA

Received: 25 March 2022 / Accepted: 19 October 2022
Published online: 14 November 2022

References
1. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease, 2021. [Internet]. 2021 [cited 2021 Oct 8]. Available from: https://goldcopd.org/.
2. Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: A systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380(9859):2095–128.
3. Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med [Internet]. 2006 Nov;3(11):e442. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17132052.
4. Atkinson RW, Kang S, Anderson HR, Mills IC, Walton HA. Epidemiological time series studies of PM2.5 and daily mortality and hospital admissions. A systematic review and meta-analysis. Thorax. 2014.

Keywords
Pulmonary and critical care, subpopulation, intermediate outcome measure, chronic obstructive pulmonary disease, spirometry, time series analysis, association, air pollution.
5. Dominici F, Peng RD, Bell ML, Pham L, McDermott A, Zeger SL, et al. Fine particulate air pollution and hospital admission for cardiovascular and respiratory diseases. J Am Med Assoc. 2006.

6. Wynn TA, Chawla A, Pollard JW. Macrophage biology in development, homeostasis and disease. Nature. 2013.

7. Vlahos R, Bozinovski S. Role of alveolar macrophages in chronic obstructive pulmonary disease. Frontiers in Immunology. 2014.

8. Yamazaki K, Van Eeden SF. Lung macrophage phenotypes and functional responses. Role in the pathogenesis of COPD. International Journal of Molecular Sciences. 2018.

9. You R, Lu W, Shan M, Berlin JM, Samuel EL, Marcano DC, et al. Nanoparticulate carbon black in cigarette smoke induces DNA cleavage and Th17-mediated emphysema. Elle [Internet]. 2015 Oct 5;4:e06923. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26437452.

10. Bai Y, Brugha RE, Jacobs L, Grigg J, Nawor TS, Nemery B. Carbon loading in airway macrophages as a biomarker for individual exposure to particulate matter air pollution - A critical review. Environment International. 2015.

11. Nwokoro C, Ewin C, Harrison C, Ibrahim M, Dundas I, Dickson I, et al. Cycling to work in London and inhaled dose of black carbon. Eur Respir J. 2012.

12. Brugha RE, Mulshtan N, Round T, Gadhrvi DH, Dundas I, Gaillard E, et al. Carbon in airway macrophages from children with asthma. Thorax. 2014.

13. Fullerton DG, Jere K, Jambo K, Kulkarni NS, Zijlstra EE, Grigg J, et al. Domestic smoke exposure is associated with alveolar macrophage particulate load. J Thorac Med Heal. 2009.

14. Belli AJ, Bose S, Aggarwal N, DaSilva C, Thapa S, Grammer L, et al. Indoor particulate matter exposure is associated with increased black carbon content in airway macrophages of former smokers with COPD. Environ Res. 2016.

15. Tejwani V, Moughames E, Suresh K, Tang S-E, Mair LG, Romero K, et al. Black Carbon Content in Airway Macrophages Is Associated with Reduced CD80 Expression and Increased Exuberance in Former Smokers With COPD. Chronic Obst Pulum Dis [Miami, Fla] [Internet]. 2020 Nov 6; Available from: http://www.ncbi.nlm.nih.gov/pubmed/33156984.

16. Dewhurst JA, Lea S, Hardaker E, Dugway JF, Ravi AK, Singh D. Characterisation of lung macrophage subpopulations in COPD patients and controls. Sci Rep. 2017.

17. Lea S, Dugway J, Ravi A, Singh D. Alveolar macrophage size is increased in COPD patients compared to controls. In 2017.

18. Hansel NN, Paulin LM, Gassett AJ, Peng RD, Alexis N, Fan VS, et al. Design of the subpopulations and intermediate outcome measures in COPD (SPIROMICS) AIR study. BMC Open Respir Res. 2017.

19. Alexis N, Soukup J, Gho A, Becker S. Sputum phagocytes from healthy individuals are functional and activated. A flow cytometric comparison with cells in bronchoalveolar lavage and peripheral blood. Clin Immunol. 2000.

20. Kulkarni NS, Frudon B, Pandit SL, Abeeve Y, Grigg J. Carbon loading of alveolar macrophages in adults and children exposed to biomass smoke particles. Sci Total Environ. 2005.

21. Sampson PD, Szpiro AA, Sheppard L, Lindström J, Kaufman JD. Pragmatic estimation of a spatio-temporal air quality model with irregular monitoring data. Atmos Environ. 2011.

22. Szpiro AA, Sampson PD, Sheppard L, Lunnley T, Adar SD, Kaufman JD. Predicting intra-urban variation in air pollution concentrations with complex spatio-temporal dependencies. Environmetrics. 2010.

23. Zusman M, Gassett AJ, Kirwa K, Barr RG, Cooper CB, Han MK, et al. Modeling Residential Indoor Concentrations of PM 2.5, NO 2, NO x, and secondhand smoke in the Subpopulations and Intermediate Outcome Measures in COPD (SPiROMICS) Air Study. Indoor Air. 2020.

24. Goniewicz ML, Esiner MD, Lazcano-ponce E, Zielinska-danch W, Kowalski B, Sovanak A, et al. Characterization of urinary cotinine and the tobacco-specific nitrosamine metabolite 1-(3-pyridyl)-1-butanol (NNAL) and their ratio to discriminate active from passive smoking. Nicotine Tob Res. 2011.

25. Standardization of Spirometry. 1994 Update. American Thoracic Society. Am J Respir Crit Care Med. 1995.

26. Jones PW, Quirk FH, Baveystock CM, Littlejohns P. A self-complete measure of health status for chronic airflow limitation. The St. George's Respiratory Questionnaire. Am Rev Respir Dis. 1992.

27. Jones PW, Harding G, Berry P, Wiklund L, Chen WH, Kline Leidy N. Development and first validation of the COPD Assessment Test. Eur Respir J. 2009.

28. Mahler DA, Wells CK. Evaluation of clinical methods for rating dyspnea. Chest. 1988.

29. Rubin BK, Ramirez O, Ohar JA. Inhaled glycerol has no effect on pulmonary function, symptom score, or sputum properties in patients with stable chronic bronchitis. Chest. 1996.

30. Kim V, Zhao H, Regan E, Han MK, Make BJ, Crapo JD, et al. The St. George’s Respiratory Questionnaire Definition of Chronic Bronchitis May Be a Better Predictor of COPD Exacerbations Compared With the Classic Definition. Chest. 2019.

31. American Thoracic Society. Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. ATS statement: Guidelines for the six-minute walk test. Am J Respir Crit Care Med. 2002.

32. Kulpniki N, Pierse N, Rushton L, Grigg J. Carbon in airway macrophages and lung function in children. N Engl J Med. 2006.

33. Klepeis NE, Nelson WC, Ott WR, Robinson JP, Tsang AM, Switzer P, et al. The National Human Activity Pattern Survey (NHAPS): A resource for assessing exposure to environmental pollutants. J Expo Anal Environ Epidemiol. 2001.

34. Beals T, Fligel S, Stuth S, Gong H, Tashkin D. Morphometry of alveolar macrophages from smokers of marijuana, tobacco, and cocaine. In: 77th Annual Meeting of the United States and Canadian Academy of Pathology. 1988.

35. Cazzola M, MacNeil W, Martinez-Ferez J, Rabe KF, Franciosi LG, Barnes PJ, et al. Outcomes for COPD pharmacological trials: From lung function to biomarkers. Eur Respir J. 2008; Vol. 31:416–68.

36. Pesco A, Balbi B, Majori M, Cacciari G, Bertacce S, Alciano P, et al. Inflammatory cells and mediators in bronchial lavage of patients with chronic obstructive pulmonary disease. Eur Respir J [Internet]. 1998 Aug;12(2):380–6. Available from: http://www.ncbi.nlm.nih.gov/pubmed/9177278.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.